---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-24-000088"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:28:20.315295+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ANI Pharma completes Alimera acquisition; expects high single-digit to low double-digit EPS accretion in 2025

## Summary
- Acquired Alimera for $5.50/share plus CVR up to $0.50/share based on 2026-27 net revenue targets; repaid $72.5M Alimera debt.
- Alimera adds ~$105M in pro forma 2024 revenue; Rare Disease segment to become ~45% of pro forma revenues.
- New capital: $316.25M 2.25% convertible notes due 2029; new $325M term loan; interest expense reduced ~$39M annually.
- Expects high single-digit to low double-digit accretion in 2025 adjusted non-GAAP EPS; substantially accretive thereafter; $35-38M adj. EBITDA.
- Cortrophin Gel record new patient starts in Aug; ophthalmology team >3,600 physicians; 14 generic products launched YTD; maintains standalone 2024 guidance.

## SEC filing metadata
- accession: 0001023024-24-000088
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000088/0001023024-24-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000088/ani-20240916.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-24-000088
- JSON: https://secwatch.observer/filing/0001023024-24-000088.json
- Plain text: https://secwatch.observer/filing/0001023024-24-000088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.